ADCYAP1R1

Protein-coding gene in the species Homo sapiens
ADCYAP1R1
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

2JOD

Identifiers
AliasesADCYAP1R1, PAC1, PAC1R, PACAPR, PACAPRI, ADCYAP receptor type I
External IDsOMIM: 102981 MGI: 108449 HomoloGene: 870 GeneCards: ADCYAP1R1
Gene location (Human)
Chromosome 7 (human)
Chr.Chromosome 7 (human)[1]
Chromosome 7 (human)
Genomic location for ADCYAP1R1
Genomic location for ADCYAP1R1
Band7p14.3Start31,052,308 bp[1]
End31,111,479 bp[1]
Gene location (Mouse)
Chromosome 6 (mouse)
Chr.Chromosome 6 (mouse)[2]
Chromosome 6 (mouse)
Genomic location for ADCYAP1R1
Genomic location for ADCYAP1R1
Band6|6 B3Start55,428,963 bp[2]
End55,478,436 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • ganglionic eminence

  • nucleus accumbens

  • caudate nucleus

  • amygdala

  • entorhinal cortex

  • internal globus pallidus

  • cingulate gyrus

  • postcentral gyrus

  • superior vestibular nucleus

  • hippocampus proper
Top expressed in
  • paraventricular nucleus of hypothalamus

  • arcuate nucleus

  • dorsomedial hypothalamic nucleus

  • ventral tegmental area

  • substantia nigra

  • lateral hypothalamus

  • ventromedial nucleus

  • dorsal tegmental nucleus

  • pontine nuclei

  • nucleus accumbens
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • G protein-coupled receptor activity
  • adenylate cyclase binding
  • neuropeptide binding
  • vasoactive intestinal polypeptide receptor activity
  • signal transducer activity
  • protein binding
  • transmembrane signaling receptor activity
  • signaling receptor activity
  • G protein-coupled peptide receptor activity
  • peptide hormone binding
Cellular component
  • cytoplasm
  • integral component of membrane
  • endosome
  • rough endoplasmic reticulum
  • membrane
  • bicellular tight junction
  • receptor complex
  • plasma membrane
  • integral component of plasma membrane
  • cell surface
  • caveola
  • neuron projection
  • intracellular membrane-bounded organelle
Biological process
  • cell differentiation
  • multicellular organismal response to stress
  • response to estradiol
  • positive regulation of calcium ion transport into cytosol
  • positive regulation of inositol phosphate biosynthetic process
  • negative regulation of cell death
  • activation of phospholipase C activity
  • multicellular organism development
  • cell surface receptor signaling pathway
  • development of primary female sexual characteristics
  • spermatogenesis
  • response to ethanol
  • cAMP-mediated signaling
  • signal transduction
  • positive regulation of small GTPase mediated signal transduction
  • G protein-coupled receptor signaling pathway
  • positive regulation of cAMP-mediated signaling
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

117

11517

Ensembl

ENSG00000078549

ENSMUSG00000029778

UniProt

P41586

P70205

RefSeq (mRNA)

NM_001118
NM_001199635
NM_001199636
NM_001199637

NM_001025372
NM_007407

RefSeq (protein)

NP_001109
NP_001186564
NP_001186565
NP_001186566

NP_001020543
NP_031433

Location (UCSC)Chr 7: 31.05 – 31.11 MbChr 6: 55.43 – 55.48 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Pituitary adenylate cyclase-activating polypeptide type I receptor also known as PAC1, is a protein that in humans is encoded by the ADCYAP1R1 gene.[5] This receptor binds pituitary adenylate cyclase activating peptide.[6][7]

Function

PAC1 is a membrane-associated protein and shares significant homology with members of the G-protein coupled class B glucagon/secretin receptor family.[8] This receptor mediates diverse biological actions of adenylate cyclase activating polypeptide 1 and is positively coupled to adenylate cyclase. Alternative splicing of two exons of this gene generates four major splice variants, but their full-length nature has not been determined.[5] PAC1 is expressed in the adrenal medulla, pancreatic acini, uterus, myenteric plexus and brain.[9][10][11] It is also expressed in the trigeminal, otic and superior cervical ganglia (prejunctional) and cerebral arteries (postjunctional).[12]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000078549 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000029778 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: ADCYAP1R1 adenylate cyclase activating polypeptide 1 (pituitary) receptor type I".
  6. ^ Ogi K, Miyamoto Y, Masuda Y, Habata Y, Hosoya M, Ohtaki T, Masuo Y, Onda H, Fujino M (Nov 1993). "Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor". Biochemical and Biophysical Research Communications. 196 (3): 1511–21. doi:10.1006/bbrc.1993.2423. PMID 7902709.
  7. ^ Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (Jun 2000). "Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions". Pharmacological Reviews. 52 (2): 269–324. PMID 10835102.
  8. ^ Wang J, Song X, Zhang D, Chen X, Li X, Sun Y, Li C, Song Y, Ding Y, Ren R, Harrington EH, Hu LA, Zhong W, Xu C, Huang X, Wang HW, Ma Y (2020). "Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism". Cell Res. 30 (5): 436–445. doi:10.1038/s41422-020-0280-2. PMC 7196072. PMID 32047270.
  9. ^ Reubi JC (2000). "In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications". Annals of the New York Academy of Sciences. 921 (1): 1–25. Bibcode:2000NYASA.921....1R. doi:10.1111/j.1749-6632.2000.tb06946.x. PMID 11193811. S2CID 21204750.
  10. ^ Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (Jun 2000). "Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin". Cancer Research. 60 (11): 3105–12. PMID 10850463.
  11. ^ Yon L, Breault L, Contesse V, Bellancourt G, Delarue C, Fournier A, Lehoux JG, Vaudry H, Gallo-Payet N (Apr 1998). "Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation" (PDF). The Journal of Clinical Endocrinology and Metabolism. 83 (4): 1299–305. doi:10.1210/jcem.83.4.4690. PMID 9543159.
  12. ^ Knutsson M, Edvinsson L (Mar 2002). "Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia". NeuroReport. 13 (4): 507–9. doi:10.1097/00001756-200203250-00030. PMID 11930171. S2CID 30329669.

Further reading

  • Stoffel M, Espinosa R, Trabb JB, Le Beau MM, Bell GI (Oct 1994). "Human type I pituitary adenylate cyclase activating polypeptide receptor (ADCYAP1R): localization to chromosome band 7p14 and integration into the cytogenetic, physical, and genetic map of chromosome 7". Genomics. 23 (3): 697–9. doi:10.1006/geno.1994.1560. PMID 7851900.
  • Ogi K, Miyamoto Y, Masuda Y, Habata Y, Hosoya M, Ohtaki T, Masuo Y, Onda H, Fujino M (Nov 1993). "Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor". Biochemical and Biophysical Research Communications. 196 (3): 1511–21. doi:10.1006/bbrc.1993.2423. PMID 7902709.
  • Ohtaki T, Masuda Y, Ishibashi Y, Kitada C, Arimura A, Fujino M (Dec 1993). "Purification and characterization of the receptor for pituitary adenylate cyclase-activating polypeptide". The Journal of Biological Chemistry. 268 (35): 26650–7. doi:10.1016/S0021-9258(19)74361-0. PMID 8253796.
  • Pisegna JR, Wank SA (Jul 1996). "Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C". The Journal of Biological Chemistry. 271 (29): 17267–74. doi:10.1074/jbc.271.29.17267. PMC 6721843. PMID 8663363.
  • Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J, Journot L (Sep 1996). "Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation". The Journal of Biological Chemistry. 271 (36): 22146–51. doi:10.1074/jbc.271.36.22146. PMID 8703026.
  • Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC (Jul 1996). "Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate". Endocrinology. 137 (7): 2815–22. doi:10.1210/en.137.7.2815. PMID 8770902.
  • Wei Y, Mojsov S (Nov 1996). "Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology". Journal of Neuroendocrinology. 8 (11): 811–7. doi:10.1046/j.1365-2826.1996.05191.x. PMID 8933357. S2CID 22302790.
  • Brabet P, Diriong S, Journot L, Bockaert J, Taviaux S (Nov 1996). "Localization of the human pituitary adenylate cyclase-activating polypeptide receptor (PACAP1-R) gene to 7p15-p14 by fluorescence in situ hybridization". Genomics. 38 (1): 100–2. doi:10.1006/geno.1996.0600. PMID 8954788.
  • Yon L, Breault L, Contesse V, Bellancourt G, Delarue C, Fournier A, Lehoux JG, Vaudry H, Gallo-Payet N (Apr 1998). "Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation" (PDF). The Journal of Clinical Endocrinology and Metabolism. 83 (4): 1299–305. doi:10.1210/jcem.83.4.4690. PMID 9543159.
  • Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE (Mar 1999). "Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis". Regulatory Peptides. 80 (1–2): 49–55. doi:10.1016/S0167-0115(99)00010-5. PMID 10235634. S2CID 8591698.
  • Zeng N, Athmann C, Kang T, Lyu RM, Walsh JH, Ohning GV, Sachs G, Pisegna JR (Nov 1999). "PACAP type I receptor activation regulates ECL cells and gastric acid secretion". The Journal of Clinical Investigation. 104 (10): 1383–91. doi:10.1172/JCI7537. PMC 409843. PMID 10562300.
  • Dautzenberg FM, Mevenkamp G, Wille S, Hauger RL (Dec 1999). "N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants". Journal of Neuroendocrinology. 11 (12): 941–9. doi:10.1046/j.1365-2826.1999.00411.x. PMID 10583729. S2CID 35761617.
  • Scaldaferri ML, Modesti A, Palumbo C, Ulisse S, Fabbri A, Piccione E, Frajese G, Moretti C (Mar 2000). "Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta". Endocrinology. 141 (3): 1158–67. doi:10.1210/endo.141.3.7346. PMID 10698193.
  • Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I (Feb 2000). "Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung". Peptides. 21 (2): 265–9. doi:10.1016/S0196-9781(99)00202-8. PMID 10764955. S2CID 44951090.
  • Knutsson M, Edvinsson L (Mar 2002). "Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia". NeuroReport. 13 (4): 507–9. doi:10.1097/00001756-200203250-00030. PMID 11930171. S2CID 30329669.
  • Miampamba M, Germano PM, Arli S, Wong HH, Scott D, Taché Y, Pisegna JR (May 2002). "Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons". Regulatory Peptides. 105 (3): 145–54. doi:10.1016/S0167-0115(02)00003-4. PMC 6736535. PMID 11959368.
  • Le SV, Yamaguchi DJ, McArdle CA, Tachiki K, Pisegna JR, Germano P (Nov 2002). "PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells". Regulatory Peptides. 109 (1–3): 115–25. doi:10.1016/S0167-0115(02)00194-5. PMC 6736540. PMID 12409223.
  • Ronaldson E, Robertson DN, Johnson MS, Holland PJ, Mitchell R, Lutz EM (Nov 2002). "Specific interaction between the hop1 intracellular loop 3 domain of the human PAC(1) receptor and ARF". Regulatory Peptides. 109 (1–3): 193–8. doi:10.1016/S0167-0115(02)00204-5. PMID 12409233. S2CID 25745650.
  • Isobe K, Tatsuno I, Yashiro T, Nanmoku T, Takekoshi K, Kawakami Y, Nakai T (Feb 2003). "Expression of mRNA for PACAP and its receptors in intra- and extra-adrenal human pheochromocytomas and their relationship to catecholamine synthesis". Regulatory Peptides. 110 (3): 213–7. doi:10.1016/S0167-0115(02)00209-4. PMID 12573802. S2CID 21201447.

External links

  • "VIP and PACAP Receptors: PAC1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
  • Human ADCYAP1R1 genome location and ADCYAP1R1 gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

  • v
  • t
  • e
Neurotransmitter
Adrenergic
Purinergic
Serotonin
Other
Metabolites and
signaling molecules
Eicosanoid
Other
Peptide
Neuropeptide
Other
Miscellaneous
Taste, bitter
Orphan
Other
Adhesion
Orphan
Other
Taste, sweet
Other
Class F: Frizzled & Smoothened
Frizzled
Smoothened
  • v
  • t
  • e
Angiopoietin
  • Kinase inhibitors: Altiratinib
  • CE-245677
  • Rebastinib
CNTF
EGF (ErbB)
EGF
(ErbB1/HER1)
ErbB2/HER2
  • Agonists: Unknown/none
ErbB3/HER3
ErbB4/HER4
FGF
FGFR1
FGFR2
  • Antibodies: Aprutumab
  • Aprutumab ixadotin
FGFR3
FGFR4
Unsorted
HGF (c-Met)
IGF
IGF-1
  • Kinase inhibitors: BMS-754807
  • Linsitinib
  • NVP-ADW742
  • NVP-AEW541
  • OSl-906
IGF-2
  • Antibodies: Dusigitumab
  • Xentuzumab (against IGF-1 and IGF-2)
Others
  • Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
  • Trofinetide
LNGF (p75NTR)
  • Aptamers: Against NGF: RBM-004
  • Decoy receptors: LEVI-04 (p75NTR-Fc)
PDGF
RET (GFL)
GFRα1
GFRα2
GFRα3
GFRα4
Unsorted
  • Kinase inhibitors: Agerafenib
SCF (c-Kit)
TGFβ
  • See here instead.
Trk
TrkA
  • Negative allosteric modulators: VM-902A
  • Aptamers: Against NGF: RBM-004
  • Decoy receptors: ReN-1820 (TrkAd5)
TrkB
TrkC
VEGF
Others